China’s first patent for a COVID-19 vaccine has been granted by the country’s National Intellectual Property Administration.
Also on Monday, South Africa’s University of Witwatersrand started the second COVID-19 vaccine trial in the country.
The Chinese patent was jointly applied for by a research team with the Academy of Military Sciences and CanSino Biologics Inc., a Chinese high-tech biopharmaceutical company, said a report in People’s Daily.
The team, led by Chen Wei, a researcher at the Institute of Military Medicine under the academy, developed the recombinant COVID-19 vaccine, with the modified defective adenovirus as the vector.
Read Also: China’s conditionality
In March, the vaccine became the first in China to be approved to enter clinical trials.
According to the patent abstract, the vaccine shows good immunogenicity in both mouse and guinea pig models and can induce strong cellular and humoral immune response in a short period of time.
It can be produced quickly on a large scale to cope with a COVID-19 outbreak.
However, Shabir Madhi, Executive Director of the South African Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit (VIDA) at Wits and the Faculty of Health Sciences Dean-elect said he would lead the Phase II trial of the NVX-CoV2373 vaccine, which is produced by U.S.-based